Proactive Investors - Run By Investors For Investors

Sareum’s SRA737 Chk1 inhibitor impresses once again

Sierra Oncology, the US firm which is licensing Sareum’s SRA737 compound, published more data overnight
lung x ray
SRA737 has demonstrated “clear anti-tumour activity” in pre-clinical tests

Sareum Holdings Plc (LON:SAR) shares were in demand on Friday morning after Sierra Oncology, the US firm which has licensed Sareum’s SRA737 checkpoint kinase 1 (Chk1) inhibitor candidate, published new data overnight.

Chk1 controls a cancer cell's response to DNA damage, which could be caused by the disease itself or intentionally caused by chemotherapy or radiotherapy.

In data presented at an industry conference in Miami on Thursday, SRA737 demonstrated “clear anti-tumour activity” in a preclinical model of small cell lung cancer.

READ: SRA737 could have potential in ovarian cancer

 “We are encouraged by the findings of this study, which was presented at AACR,” said Sareum chief executive Tim Mitchell.

“It showed SRA737 activated the innate immune signalling Stimulator of Interferon Genes (STING) pathway and demonstrated clear anti-tumour activity in an immunocompetent preclinical model of small cell lung cancer.

“These are important findings as SCLC remains a significant unmet need and one where immunotherapies have yielded limited efficacy. These encouraging preclinical results highlight an additional potential opportunity for SRA737 that warrants further evaluation.”

Research house Hybridan added: “This data bodes well for a potential immunotherapy combination study in humans, which if successful further augments the potential scale of future royalties to Sareum, as well as the likelihood of further success milestones.”

Shares rose 5.7% to 0.74p in early deals on Friday.

View full SAR profile View Profile

Sareum Holdings PLC Timeline

Big Picture
February 22 2019

Related Articles

Cancer cells
February 06 2019
In October 2018, Maxcyte saw the first patient dosed in an initial phase I trial using its lead MCY-M11 therapy, tracking a total of 15 women with relapsed or hard-to-treat forms of cancer
May 09 2019
Here we take a look under the hood of Shield Therapeutics
genedrive device
May 23 2019
Here we take a closer look at Genedrive PLC (LON:GDR)

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use